Avitide Inc. (“Avitide”) a US-based pioneer in the development of proprietary affinity purification solutions, has been sold to Repligen Corporation (“Repligen”). The acquisition will strengthen Repligen’s Proteins business and move Repligen into affinity resin solutions for gene therapy.
Repligen has entered into a definitive agreement to acquire Avitide Inc., for approximately $150 million in upfront payment, comprised of $75 million in cash plus $75 million in Repligen common stock, in addition to earnout payments based on various milestones.
Avitide, based in Lebanon, NH, is a leading chromatography developer with diverse affinity ligand libraries and best-in-class ligand-to-resin development timelines.
Repligen is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Repligen is inspiring advances in bioprocessing for the customers it serves; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide.
EC M&A acted as exclusive M&A advisor to Avitide on this transaction.
